在体内通过尼奥索姆和素作为纳米辅助剂改善西斯普拉丁化疗
Ebtesam A Mohamad1,2, Marwa R El-Garhy3, Monira M Rageh3
1Biophysics Department, Faculty of Science, Cairo University, Giza, Egypt. imohamed@sci.cu.edu.eg.
Medical oncology (Northwood, London, England)
|November 5, 2025
概括
和素的体封装增强了低剂量西斯的作用.
科学领域:
- 在瘤学瘤学.
- 纳米技术 纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 全球乳腺癌发病率正在上升.
- 西斯普拉丁是一种常见的化疗药物,具有有毒副作用.
- 和素等天然化合物在癌症治疗中显示出潜在的潜力.
研究的目的:
- 为了评估 (EEP) 和 (Chry) 的体封装乙醇提取物的抗癌潜力.
- 为了研究这些尼奥索姆配方与低剂量西斯普拉丁相结合的协同效应 in vivo.
- 评估对瘤生长,组织学,氧化应激和全身毒性的影响.
主要方法:
- 使用GC-MS.EEP的植物化学分析.
- 对于EEP和Chry的尼奥索姆封装,然后进行表征 (TEM,DLS,泽塔潜力,UV-Vis,FTIR).
- 在体内研究使用埃里希癌诱导的小鼠,评估十个治疗组的瘤生长,组织学和组织毒性.
主要成果:
- 对于EEP和Chry.来说,体封装实现了高稳定性和封装效率 (90%).
- 与对照组相比,组合治疗显著减少了约90%的瘤体积.
- 尼奥索姆EEP和Chry与低剂量西斯普拉丁一起增强了抗氧化活性,并减少了线粒细胞的数量,同时增加了瘤的缩.
- 这些组合表明对西斯普拉丁诱导的肝毒性和毒性有保护作用.
结论:
- 体EEP和Chry有效地增强了低剂量西斯的抗瘤疗效.
- 这种纳米载体方法最大限度地减少了与化疗相关的全身毒性.
- 体天然辅助剂代表了结合癌症治疗的有希望的策略.
更多相关视频
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
11.4K
05:55Synthesis and Characterization of Placental Chondroitin Sulfate A plCSA-Targeting Lipid-Polymer Nanoparticles
Published on: September 18, 2018
9.2K
相关概念视频
02:49Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
556
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
556